Gut Hormones as Peripheral Anti-Obesity Targets: The Drug Development Landscape

Gut hormones (GLP-1, PYY, oxyntomodulin, amylin, PP, CCK) represent the most tractable peripheral targets for obesity drugs, with GLP-1 agonists and PYY analogs leading the clinical pipeline.

Small, Caroline J et al.·Current drug targets. CNS and neurological disorders·2004·Moderate EvidenceReview
RPEP-00978ReviewModerate Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Peripheral gut hormone-based obesity drug development focuses on GLP-1 agonists (most advanced), PYY analogs, oxyntomodulin, amylin analogs, and PP as practical anti-obesity drug targets with established physiological rationale and clinical precedent.

Key Numbers

How They Did This

review study on glp-1, neuropeptides.

Why This Research Matters

Relevant for glp-1, neuropeptides, weight-loss, clinical-trials.

The Bigger Picture

Advances peptide therapeutics research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Peripheral gut hormone-based obesity drug development focuses on GLP-1 agonists (most advanced), PYY analogs, oxyntomodulin, amylin analogs, and PP as
Evidence Grade:
moderate evidence.
Study Age:
Published in 2004.
Original Title:
Gut hormones as peripheral anti obesity targets.
Published In:
Current drug targets. CNS and neurological disorders, 3(5), 379-88 (2004)
Database ID:
RPEP-00978

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Gut Hormones as Peripheral Anti-Obesity Targets: The Drug Development Landscape

What was found?

Gut hormones (GLP-1, PYY, oxyntomodulin, amylin, PP, CCK) represent the most tractable peripheral targets for obesity drugs, with GLP-1 agonists and PYY analogs leading the clinical pipeline.

Read More on RethinkPeptides

Cite This Study

RPEP-00978·https://rethinkpeptides.com/research/RPEP-00978

APA

Small, Caroline J; Bloom, Stephen R. (2004). Gut hormones as peripheral anti obesity targets.. Current drug targets. CNS and neurological disorders, 3(5), 379-88.

MLA

Small, Caroline J, et al. "Gut hormones as peripheral anti obesity targets.." Current drug targets. CNS and neurological disorders, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Gut hormones as peripheral anti obesity targets." RPEP-00978. Retrieved from https://rethinkpeptides.com/research/small-2004-gut-hormones-as-peripheral

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.